trending Market Intelligence /marketintelligence/en/news-insights/trending/Vp8YCD-OBauKzIQ-_EtYCQ2 content esgSubNav
In This List

US FDA approves Endo's application for low blood pressure injection

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


US FDA approves Endo's application for low blood pressure injection

Endo International PLC's operating company Par Pharmaceutical received final approval from the U.S. FDA for its new drug application for ephedrine sulfate injection.

The drug is a parenterally administered pressor agent to address hypotension, which is low blood pressure, in surgical settings.

U.S. sales of ephedrine sulfate injection products were about $177 million for the 12 months ended Nov. 30, 2016, according to IMS Health data.

Par Pharmaceutical anticipates shipping of the product to begin in February.